Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 803 participants.

Also called NCT01926782

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 803 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01926782
Other papers using this trial's data
  • A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I Atherosclerosis, 2016-11 DOI, PubMed 27639753
  • Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial Journal of clinical lipidology, 2020 DOI, PubMed 32928709

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Canada, Hungary, Israel, Norway, Slovakia, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01926782. Randomized; quadruple masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2014-09 (actual). Results posted on 2017-03-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
Condition
Hypercholesterolemia
Intervention (Drug)
Placebo (for alirocumab)
Intervention (Drug)
Alirocumab
Intervention (Drug)
Statin
Lead sponsor
Regeneron Pharmaceuticals (class: industry)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01926782
Content hash
4c5d7e8de6b8443b10c119143dd92348e171d7e86bfbababbe547f9cd8df5ba5